Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Friday . The stock had previously closed at $68.6950, but opened at $64.0750. Zealand Pharma A/S shares last traded at $64.0750, with a volume of 153 shares changing hands.

Wall Street Analysts Forecast Growth

ZLDPF has been the subject of several recent research reports. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. Five research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Zealand Pharma A/S Stock Performance

The firm’s 50 day simple moving average is $71.79 and its 200 day simple moving average is $69.94. The firm has a market cap of $4.55 billion, a PE ratio of 4.61 and a beta of 0.72. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The firm had revenue of $7.76 million during the quarter, compared to the consensus estimate of $4.54 million. On average, research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.